# Indraprastha (NSE: IGL) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/IGL · Pivot · prices to 22 Oct 2026

Indraprastha (NSE: IGL) closed at ₹141.87 on 22 Oct 2026, down 0.11% on the day. With a market capitalisation of ₹19,862 Cr, it ranks 357th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Utilities - Regulated Gas.

At its last close the stock traded at 12.8× trailing earnings, against a return on equity of 27.0% in FY25. Over the past year the share price has fallen 33.1%. Its 52-week range is ₹139.20 (29 Sep 2026) to ₹219.10 (4 Nov 2025); the last close is 35.2% below the high. Promoters held 45.00% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹141.87 |
| Market cap | ₹19,862 Cr |
| P/E (trailing) | 12.8 |
| ROE | 27.0% (FY25) |
| ROCE | 33.1% (FY25) |
| Debt to equity | 0 |
| 52-week high | ₹219.10 (4 Nov 2025) |
| 52-week low | ₹139.20 (29 Sep 2026) |
| 1-year return | −33.1% |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹1,356 Cr | ₹161 Cr |
| FY24 | ₹1,245 Cr | ₹124 Cr |
| FY23 | ₹1,099 Cr | ₹86 Cr |
| FY22 | ₹888 Cr | ₹59 Cr |
| FY21 | ₹613 Cr | ₹2 Cr |
| FY20 | ₹831 Cr | ₹44 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 45.00%
- Foreign institutions: 10.16%
- Domestic institutions: 30.03%
- Non-institutions: 9.81%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Procter Gamble](https://app.pivotnow.in/stock/PGHH) | ₹6,856.00 | ₹22,255 Cr | 26 | — |
| [Piramal Phytoca](https://app.pivotnow.in/stock/PIRPHYTO) | — | ₹21,083 Cr | — | — |
| [SAGILITY](https://app.pivotnow.in/stock/SAGILITY) | ₹44.78 | ₹20,963 Cr | 22.6 | — |
| [Granules India](https://app.pivotnow.in/stock/GRANULES) | ₹807.65 | ₹20,013 Cr | 33 | — |
| [Cohance Lifesciences](https://app.pivotnow.in/stock/COHANCE) | ₹460.30 | ₹17,610 Cr | 98.6 | — |
| [Shilpa Medicare](https://app.pivotnow.in/stock/SHILPAMED) | ₹880.90 | ₹17,229 Cr | 70.9 | — |

## Questions and answers

### What is the share price of Indraprastha today?

Indraprastha (NSE: IGL) last closed at ₹141.87 on 22 Oct 2026. Its 52-week high is ₹219.10 and its 52-week low is ₹139.20.

### What is the market cap of Indraprastha?

Indraprastha's market capitalisation is ₹19,862 Cr (₹19,862 Cr) at the 22 Oct 2026 close, ranking 357th among the NSE companies Pivot tracks.

### What is the P/E ratio of Indraprastha?

Indraprastha trades at a trailing P/E of 12.8. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 33.

### What is the ROE and ROCE of Indraprastha?

Return on equity was 27.0% in FY25 and return on capital employed was 33.1% in FY25 (standalone figures).

### Is Indraprastha a debt-free company?

Indraprastha is close to debt-free: its debt-to-equity ratio was 0 in FY25.

### How has Indraprastha stock performed over the last year?

Indraprastha's share price has fallen 33.1% over the past year, −6.2% over three months and −4.7% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Indraprastha?

As of 30 Jun 2026: promoters 45.00%, foreign institutions 10.16%, domestic institutions 30.03%, non-institutions 9.81%.

### Who are Indraprastha's competitors?

The listed Pharma & Healthcare companies closest to Indraprastha by market cap are Procter Gamble, Piramal Phytoca, SAGILITY, Granules India, Cohance Lifesciences and Shilpa Medicare.

### Is Indraprastha a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Indraprastha's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on IGL against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.